UK biotech firms eye Nasdaq listings

Aidan Gregory

January 19, 2021 12:00 pm

Vaccitech_PA_575_375 — Laboratory technicians at the manufacturing facility for the Oxford/Astrazeneca vaccine at Oxford Biomedica in Oxfordshire. Picture date: Monday January 18, 2021. | Heathcliff O'Malley/The Daily Telegraph/PA

Immunocore, the UK biotech company, has filed for an IPO on the Nasdaq in New York following a $75m series ‘C’ funding round which concluded last week.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

JP Morgan Equity IPOs Health and Biotech Equity UK Europe EMEA SRI Jefferies LLC Goldman Sachs

AG

Aidan Gregory